



PTO/SB/08B
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/054,350
				Filing Date	01/19/02
				First Named Inventor	Jeffrey O. Phillips
				Art Unit	1625
				Examiner Name	Fan, J.
Sheet	1	of	1	Attorney Docket Number	02936354

NON PATENT LITERATURE			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
QJ	1	TABATA, T., et al., "Stabilization of a New Antiulcer Drug (Lansoprazole) in the Solid Dosage Forms, Drug Development and Industrial Pharmacy, 18(13), 1437-1447, (1992).	
QJ	2	KROMER, et al., Differences in pH-Dependent Activation Rate of Substituted Benzimidazoles and Biological in vitro Correlates", <u>Pharmacology</u> , Vol. 56, pp. 57-70, (1998)	

Examiner Signature	Jane T. Fan	Date Considered	9/29/03
-----------------------	-------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
AUG 08 2003
TECH CENTER 1600/2900



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/054,350
				Filing Date	01/19/02
				First Named Inventor	Jeffrey O. Phillips
				Art Unit	1625
				Examiner Name	Fan, J.
Sheet	1	of	1	Attorney Docket Number	02936354

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
J.T.	1	5876759	03/02/99	Gowan, Jr.	
	2	2002 0025342 A1	02/28/02	Linder, R., et al.	
	3	2002 0192299 A1	12/19/2002	Taneja, R., et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
J.T.	4	EPO 0636364 B1	09/20/00			
	5	JP 2000 355540	12/26/00			X
	6	WO 03017980 A1	03/06/03			
	7	WO 9702020	01/23/97			
	8	WO 9702021	01/23/97			

Examiner Signature	Jane T. Fan	Date Considered	9/29/03
-----------------------	-------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

RECEIVED
AUG 08 2003
TECH CENTER 1600/2900

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936654

Sheet	1	of	9
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

↑		4045564	08/30/77	Berntsson, et al.	RECEIVED JUL 29 2003 TECH CENTER 1600/2900
		4182766	01/08/80	Krasso, et al.	
		4255431	03/10/81	Junggren, et al.	
		4255431	03/10/81	Junggren, et al.	
		4337257	06/29/82	Junggren, et al.	
		4359465	11/16/82	Ruwart	
		4414216	11/08/83	Kawakita, et al.	
		4472409	09/18/84	Senn-Bilfinger	
		4508905	04/02/85	Junggren, et al.	
		4544750	10/01/85	Brandstrom, et al.	
g.f.		4620008	10/28/86	Brandstrom, et al.	
		4636499	01/13/87	Brandstrom, et al.	
/		4725691	02/16/88	Brandstrom, et al.	
		4738974	04/19/88	Brandstrom, et al.	
reviewed		4786505	11/22/88	Lovgren, et al.	
		4853230	08/01/89	Lovgren, et al.	
		4965351	10/23/90	Caruso, et al.	
		4985548	01/15/91	Caruso, et al.	
Phosory		5008278	04/16/91	Brandstrom, et al.	
		5013743	05/07/91	Iwahi, et al.	
		5019584	05/28/91	Brandstrom, et al.	
		5025024	06/18/91	Brandstrom, et al.	
		5039806	08/13/91	Brandstrom, et al.	
		5045321	09/03/91	Makino, et al.	
		5075323	12/24/91	Fain, et al.	
		5093132	03/03/92	Makino, et al.	
		5093342	03/03/92	Tomoi, et al.	
		5106862	04/21/92	Briving, et al.	
		5124158	06/23/92	Ruwart, et al.	
		5215974	06/01/93	Alminger, et al.	
		5219870	06/15/93	Kim	
		5232706	08/03/93	Coll	
↓		5244670	09/14/93	Upson, et al.	

cursor, reviewed / g.f.

RECEIVED
JUL 29 2003
TECH CENTER 1600/2900

Dr. Fan

Date Considered 9/29/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kind's Code of USPTO Patent Documents at www.uspto.gov/mpep 901.04. *Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUL 25 2003

PTO/SB/08A
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936654

Sheet 2 of 9

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.†	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
--------------------	-----------	---	------------------------------	--	---

↑		5288506	02/22/94	Spickett, et al.	
		5339700	08/23/94	Wright, et al.	
		5374730	12/20/94	Slemon, et al.	
		5374730	12/20/94	Slemon, et al.	
		5385739	01/31/95	Debregeas, et al.	
		5385739	01/31/95	Debregeas, et al.	
		5386032	01/31/95	Brandstrom	
		5386032	01/31/95	Brandstrom	
		5391752	02/21/95	Hoerrner, et al.	
		5391752	02/21/95	Hoerrner, et al.	
		5395323	03/07/95	Berglund	
		5395323	03/07/95	Berglund	
		5399700	03/21/95	Min, et al.	
		5399700	03/21/95	Min, et al.	
		5417980	05/23/95	Goldman, et al.	
		5417980	05/23/95	Goldman, et al.	
		5430042	07/04/95	Lindberg, et al.	
		5430042	07/04/95	Lindberg, et al.	
		5447918	09/05/95	McCullough	
		5447923	09/05/95	Castrenich, et al.	
		5447923	09/05/95	Castrenich, et al.	
		5470983	11/28/95	Slemon, et al.	
		5470983	11/28/95	Slemon, et al.	
		5504082	04/02/96	Kawakita, et al.	
		5589491	12/31/96	Nakanishi, et al.	
		5599794	02/04/97	Eek, et al.	
		5629305	05/13/97	Eek, et al.	
		5633244	05/27/97	Eek, et al.	
		5639478	06/17/97	Makino, et al.	
		5690960	11/25/97	Bengtsson, et al.	
		5693818	12/02/97	Von Unge	
		5714504	02/03/98	Lindberg, et al.	
		5714505	02/03/98	Hasselkus	

Cursory reviewed J.F.

RECEIVED
JUL 29 2003
TECH CENTER 1600/2800

J.F. Fan	Date Considered 9/29/03
----------	-------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ***Applicant is to place a check mark here if English language Translation or abstract is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/054,350
			Filing Date	01/19/2002
			First Named Inventor	Jeffery O. Phillips
			Art Unit	1625
			Examiner Name	Fan, J.
			Attorney Docket Number	02936654
Sheet	3	of	9	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YY		

		5731002	03/24/98	Olovson, et al.	
		5753265	05/19/98	Bergstrand, et al.	
		5766622	06/16/98	Nelson	
		5766622	06/16/98	Nelson	
		5776765	07/07/98	Graham, et al.	
		5798120	08/25/98	Tomohisa, et al.	
		5814338	09/29/98	Veronesi	
		5817338	10/06/98	Bergstrand, et al.	
		5840737	11/24/98	Phillips	
		5877192	03/02/99	Lindberg, et al.	
		5879708	03/09/99	Makino, et al.	
		5883102	03/16/99	Hamley, et al.	
		5885594	03/23/99	Nilsen, et al.	
		5900424	05/04/99	Kallstrom, et al.	
		5929244	07/27/99	Von Unge	
		5939091	08/17/99	Eoga, et al.	
		5948789	09/07/99	Larsson, et al.	
		5955107	09/21/99	Augello, et al.	
		5958955	09/28/99	Gustavsson, et al.	
		5962022	10/05/99	Bolt, et al.	
		5965162	10/12/99	Fuisz, et al.	
		5972389	10/26/99	Shell, et al.	
		5979515	11/09/99	Olsson	
		6013281	01/11/00	Lundberg, et al.	
		6017560	01/25/00	Makino, et al.	
		6090827	07/18/00	Erickson, et al.	
		6123962	09/26/00	Makino, et al.	
		6124464	09/26/00	Hogberg, et al.	
		6132770	10/17/00	Lundberg	
		6132771	10/17/00	Depui, et al.	
		6136344	10/24/00	Depui, et al.	
		6136344	10/24/00	Depui, et al.	
		6143771	11/07/00	Lindberg, et al.	

	Date Considered	9/29/03
---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED

JUL 29 2003
TECH CENTER 1600/2900

↑
cursory reviewed J.F.
↓

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

JUL 25 2003

Complete if Known

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936654

Sheet 4 of 9

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

J.T.F.		6147103	11/14/00	Anousis, et al.	
		6150380	11/21/00	Lovqvist, et al.	
		6162816	12/19/00	Bohlin, et al.	
		6166213	12/26/00	Anousis, et al.	
		6183776	02/06/01	Depui, et al.	
		6274173	08/14/01	Sachs, et al.	
		6284271	09/04/01	Lundberg, et al.	
		2002/0102200 A1	12/19/02	Taneja, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			

Cursing revised		CA 1234118	03/15/88	Haessle AB	
		DK 19752843	07/01/99		
		EP 0005129 A1 & B1	10/31/79	Haessle AB	
		EP 0040630 A1 & B1	12/02/81	Yoshitomi Pharm	
		EP 0237200 B1	07/01/92	Takeda Chem Corp	
		EP 0244380 A2 & B1	11/04/87	Haessle AB	
		EP 0247983 A2 & B1	12/02/87	Haessle AB	
		EP 0248634 A2 & B1	07/21/93	Nippon Chemiphar Co	
		EP 0308515 A1 & B1	03/29/89	Yoshitomi Pharm	
		EP 0315964 A1 & B1	05/17/89	Fujisawa Pharm Co	
		EP 0338861 B1	01/20/93	Walton SA	
		EP 0394471 A1	10/31/90	Yoshitomi Pharm	
		EP 0414847 B1	03/06/91	Haessle AB	
		EP 0436620 B1	07/17/91	Dalsgaard, K.	
		EP 0452697 A1 & B1	10/23/91	Fujisawa Pharm Co	
		EP 0465254 A1	01/08/92	Yoshitomi Pharm	
		EP 0496437 A2, B1 & A3	07/29/92	Haessle AB	
		EP 0502556 A1 & B1	09/09/92	Haessle AB	
		EP 0565210 A2, A3 & B1	10/13/93	Haessle AB	
		EP 0567201 A2, A3 & B1	10/27/93	Haessle AB	

Jane T. Fan

Date
Considered

9/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED

JUL 29 2003
TECH CENTER 16012900

Substitute for form 1449/PTO			Complete if Known		
			Application Number	10/054,350	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Filing Date	01/19/2002	
			First Named Inventor	Jeffery O. Phillips	
JUL 25 2003			Art Unit	1625	
			Examiner Name	Fan, J.	
Sheet	5	of	9	Attorney Docket Number	02936654

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. †	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	‡
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

↑		EP 0567643 A1	11/03/93	Yoshitomi Pharm		
		EP 0587659 B1	03/23/94	Kabi Pharmacia AB		
		EP 0652751 B1	05/17/95	Astra AB		
		EP 0654471 A1 & B1	05/24/95	Eisai Co Ltd		
		EP 0696921 B1	02/21/96	Astra AB		
		EP 1004305 A1	05/21/00	Eisai Co Ltd		
		ES 2024993	12/31/90	Gen Para La Investigacion		
		GB 2189698	11/04/87	Haessle AB		
		JP 02 022225	01/25/90	Eisai Co Ltd		X
		JP 03 034967	02/14/91	Yoshitomi Pharmaceutical		X
		JP 03 048680	03/01/91	Yoshitomi Pharmaceutical		X
		JP 03 052887	03/07/91	Yoshitomi Pharmaceutical		X
		JP 03 163018	11/20/90	Takeda Chem Ind Ltd		X
		JP 05 117268	05/14/93	Yoshitomi Pharmaceutical		X
		JP 05 194224	08/03/93	Yoshitomi Pharmaceutical		X
		JP 05 194225	08/03/93	Yoshitomi Pharmaceutical		X
		JP 05 255088	10/05/93	Yoshitomi Pharmaceutical		X
		JP 05 294831	11/09/93	Haessle AB		X
		JP 06 092853	04/05/94	Fujisawa Pharm Co		X
		JP 06 100449	04/12/94	Yoshitomi Pharmaceutical		X
		JP 07 033659	02/03/95	Yoshitomi Pharmaceutical		X
		JP 09 087110	03/31/97	Yoshitomi Pharmaceutical		X
		JP 10 017470	01/20/98	Yoshitomi Pharmaceutical		X
		JP 10 017471	01/20/98	Yoshitomi Pharmaceutical		X
		JP 45 039541	12/12/70	Yoshitomi Pharmaceutical		X
		JP 45 039543	12/12/70	Yoshitomi Pharmaceutical		X
		JP 46 009580	11/03/71	Yoshitomi Pharmaceutical		X
		JP 46 009581	11/03/71	Yoshitomi Pharmaceutical		X
		JP 48 103567	12/25/73	Japan Chem Ind KK		X
		JP 49 005967	01/19/74	Yoshitomi Pharmaceutical		X
		JP 49 013172	02/05/74	Yoshitomi Pharmaceutical		X

Dr Fan	Date Considered	9/29/03
--------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ***Applicant is to place a check mark here if English language Translation or abstract is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

JUL 25 2003

Complete if Known

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936654

Sheet	6	of	9
-------	---	----	---

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴	
↑		JP 49 020173	02/22/74	Yoshitomi Pharmaceutical		X	
		JP 49 020174	02/22/74	Yoshitomi Pharmaceutical		X	
		JP 49 041198	07/11/74	Yoshitomi Pharmaceutical		X	
		JP 49 093537	09/05/74	Yoshitomi Pharmaceutical		X	
		JP 49 095997	09/11/74	Yoshitomi Pharmaceutical		X	
		JP 50 052065	05/09/75	Yoshitomi Pharmaceutical		X	
		JP 50 112373	09/03/75	Yoshitomi Pharmaceutical		X	
		JP 50 142565	11/17/75	Yoshitomi Pharmaceutical		X	
	↓		JP 51 016669	02/10/76	Yoshitomi Pharmaceutical		X
			JP 51 131875	11/16/76	Yoshitomi Pharmaceutical		X
		JP 52 005769	01/17/77	Yoshitomi Pharmaceutical		X	
		JP 52 014776	02/03/77	Yoshitomi Pharmaceutical		X	
		JP 52 097978	08/17/77	Yoshitomi Pharmaceutical		X	
		JP 52 102416	08/27/77	Okawara Mfg		X	
		JP 53 059675	05/29/78	Yoshitomi Pharmaceutical		X	
		JP 55 019211	05/24/80	Mitsui Toatsu Chem Inc		X	
		JP 56 061311	05/26/81	Fujisawa Pharmaceutical		X	
		JP 59 095997	06/02/84	Hitachi Plant Kensetsu KK		X	
Car Sony		JP 61 221117	10/01/86	Fujisawa Pharmaceutical		X	
		JP 62 145083 A	06/29/87	Yoshitomi Pharmaceutical		X	
		JP 62 258316 A	11/10/87	Haessle AB		X	
		JP 62 258320 A	11/10/87	Haessle AB		X	
		JP 62 277322 A	12/02/87	Takeda Chem Ind Ltd		X	
		JP 62 283964	12/09/87	Nippon Chemiphar Co Ltd		X	
		JP 2000 212180	02/08/00	Welfide Corp		X	
		KR 9603605 B1	03/20/96	Yungjin Pharmaceutical		X	
		KR 9611238 B1	08/21/96	Kolon Inc		X	
		KR 9611390 B1	08/22/96	Kolon Inc		X	
	RO 88351	04/30/86	Puscos, I.				
	WO 0001372 A1 & A3	01/13/00	Colman Products Ltd				
	WO 0009092 A1	02/24/00	Byk Gulden Lomberg Chem				

RECEIVED

JUL 29 2003

TECH CENTER 1600/2900

Date
Considered

9/29/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/054,350
			Filing Date	01/19/2002
			First Named Inventor	Jeffery O. Phillips
			Art Unit	1625
			Examiner Name	Fan, J.
			Attorney Docket Number	02936654
Sheet	7	of	9	

JUL 25 2003
PATENT & TRADEMARK OFFICE

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

		WO 0010999 A2 & A3	03/02/00	Dahlstroem, M.		
		WO 0015195 A1	03/23/00	Ruckendorfer, H.		
		WO 0026185 A2 & A3	05/11/00	Univ Missouri		
		WO 0027366 A1	05/18/00	Astrazeneca AB		
		WO 0028975 A2 & A3	05/25/00	Astrazeneca AB		
		WO 0030612 A1	06/02/00	Astrazeneca AB		
		WO 0035448 A1	06/22/00	Astrazeneca AB		
		WO 0044744 A1	08/03/00	Astrazeneca AB		
		WO 0045817 A1	08/10/00	Astrazeneca AB, et al.		
		WO 0050038 A1	08/31/00	Freehauf, Keith		
		WO 0069438 A1	11/23/00	Astrazeneca AB		
		WO 0078293 A1	12/28/00	Astrazeneca AB		
		WO 0103707 A1	01/18/01	SmithKline Beecham Corp		
		WO 0124780 A2	04/12/01	Natco Pharmaceutical		
		WO 0134573 A1	05/17/01	Pharmacia AB		
		WO 8900566 A1	01/26/89	Yoshitomi Pharmaceutical		
		WO 9204898 A1	04/02/92	Byk Gulden Lomberg Chem		
		WO 9208716 A1	05/29/92	Byk Gulden Lomberg Chem		
		WO 9305770 A1	04/01/93	Fujisawa Pharmaceutical		
		WO 9400112	01/06/94	Astra AB		
		WO 9402140 A1	02/03/94	Yoshitomi Pharmaceutical		
		WO 9402141 A1	02/03/94	Astra AB		
		WO 9501783 A1	01/19/95	Astra AB		
		WO 9507913 A1	03/23/95	Meiji Milk Prod Co Ltd		
		WO 9515962 A1	06/15/95	Astra AB		
		WO 9523594 A1	09/08/95	Gergely, Gerhard		
		WO 9532957 A1	12/07/95	Astra AB		
		WO 9532959 A1	12/07/95	Astra AB		
		WO 9601612 A1	01/25/96	Therapicon SRL		
		WO 9601622 A1	01/25/96	Astra AB		
		WO 9601623 A1	01/25/96	Astra AB		

Cursory reviewed - J.F.

RECEIVED
JUL 29 2003
TECH CENTER 1600/2901

Examiner: J.P. Fan	Date Considered: 9/29/03
--------------------	--------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ³Applicant's unique citation designation number (optional). ⁴See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ⁵Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁷Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation or abstract is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) JUL 25 2003			Application Number	10/054,350
			Filing Date	01/19/2002
			First Named Inventor	Jeffery O. Phillips
			Art Unit	1625
			Examiner Name	Fan, J.
			Attorney Docket Number	02936654
Sheet	8	of	9	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.†	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†

		WO 9601624 A1	01/25/96	Astra AB		
		WO 9601625 A1	01/25/96	Astra AB		
		WO 9602236 A1	02/01/96	Moore, Trevor		
		WO 9616959 A1	06/06/96	Astra AB		
		WO 9624338 A1	08/15/96	Astra AB		
		WO 9624375 A1	08/15/96	Astra AB		
		WO 9638175 A1	12/05/96	Takeda Chem Ind Ltd		
		WO 9709964 A1	03/20/97	Astra AB		
		WO 9725030 A1	07/17/97	Astrazeneca AB		
		WO 9725064 A1	07/17/97	Astrazeneca AB		
		WO 9725065 A1	07/17/97	Astrazeneca AB		
		WO 9725066 A1	07/17/97	Astra AB		
		WO 9741114 A1	11/06/97	Astra AB		
		WO 9748380 A1	12/24/97	Astra Aktiebolag		
		WO 9800114 A2	01/08/98	Klinge Co Chem Pharm		
		WO 9802368 A1	01/22/98	Merck Patent GMBH		
		WO 9816228 A1	04/23/98	Astra AB		
		WO 9828294 A1	07/02/98	Astrazeneca AB		
		WO 9840054 A1	09/17/98	Astra AB		
		WO 9850019 A1	11/12/98	Sage Pharmaceuticals		
		WO 9853803 A1	12/03/98	Astrazeneca AB		
		WO 9854171 A1	12/03/98	Astrazeneca AB		
		WO 9900380 A1	01/07/99	Astrazeneca AB		
		WO 9908500 A2	02/25/99	Astra AB		
		WO 9925323 A1	05/27/99	AndRx Pharmaceuticals		
		WO 9925711 A1	05/27/99	Astrazeneca AB		
		WO 9927917 A1	06/10/99	Byk Gulden Lomberg Chem		
		WO 9929299 A1	06/17/99	Byk Gulden Lomberg Chem		
		WO 9929320 A1	06/17/99	Byk Gulden Lomberg Chem		
		WO 9932091 A1	07/01/99	Astra AB		
		WO 9932093 A1	07/01/99	Astra AB		

J. Fan Date Considered	9/29/03
---------------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
JUL 29 2003
TECH CENTER 1600/29

Substitute for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/054,350	
				Filing Date	01/19/2002	
				First Named Inventor	Jeffery O. Phillips	
				Art Unit	1625	
				Examiner Name	Fan, J.	
Attorney Docket Number	02936654					
Sheet	9	of	9			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†

Cursory reviewed.	WO 9945004 A1	09/10/99	Nicox SA		
	WO 9953918 A1	10/28/99	Eisai Co Ltd		
	WO 9955705 A1	11/04/99	Astrazeneca AB		
	WO 9955706 A1	11/04/99	Astrazeneca AB		

RECEIVED
 JUL 29 2003
 TECH CENTER 1600/2300

	Date Considered	9/29/03
---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ³Applicant's unique citation designation number (optional). ⁴See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁵Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁷Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸Applicant is to place a check mark here if English language Translation or abstract is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936354

Sheet 1 of 12

RECEIVE

JUL 29 2003

TECH CENTER 1600/

NON PATENT LITERATUREExaminer
Initials*Cite
No.¹

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

↑		"Agents for Control of Gastric Acidity and Treatment of Peptic Ulcers", Chapter 37, pp. 907-909, 1768.
		"Buffered and Isotonic Solutions", <u>Physical Pharmacy</u> , Chapter 8, pp. 169-189.
		"Gastrointestinal Drugs", <u>The American Medical Association Drug Evaluation</u> , Vol. 2, The American Medical Association, Chicago, 1:8 (Bennett & Dickson, eds.).
		ADAMS, S. P., et al., "Comments on the Report of 'association' of Omeprazole with DNA by Phillips, et al.", <u>Mutagenesis</u> , Vol. 7, No. 5, pp. 395-396 (September 1992).
		AL-ASSI, et al., "Treatment of Helicobacter Pylori Infection With Omeprazole-Amoxicillin Combination Therapy Versus Ranitidine/Sodium Bicarbonate-Amoxicillin", <u>The American Journal of Gastroenterology</u> , Vol. 90, No. 9, pp. 1411-14 (September 1995).
		ANDERSSON, et al., "Pharmacokinetic Studies With Esomeprazole, the (S)-Isomer of Omeprazole", <u>Clinical Pharmacokinetics</u> , Vol. 40, No. 6, pp. 411-426 (2001).
		ANDERSSON, T., "Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors: Focus on Omeprazole, Lansoprazole and Pantoprazole", <u>Clin. Pharmacokinet.</u> , Vol. 31, No. 1, pp. 9-28 (July 1996).
		ANDERSSON, T., et al., "Pharmacokinetics and Bioavailability of Omeprazole After Single and Repeated Oral Administration in Healthy Subjects", <u>Br. J. Clin. Pharmac.</u> , Vol. 29, pp. 557-563 (1990).
		ANDERSSON, T., et al., "Pharmacokinetics of [¹⁴ C]Omeprazole in Patients with Liver Cirrhosis", <u>Clin Pharmacokinet.</u> , Vol. 24, No. 1, pp. 71-78 (1993).
		ANDERSSON, T., et al., "Pharmacokinetics of Various Single Intravenous and Oral Doses of Omeprazole", <u>European Journal of Clinical Pharmacology</u> , Vol. 39, pp. 195-197 (1990).
		ARVIDSSON, et al., "Peak Distortion in the Column Liquid Chromatographic Determination of Omeprazole Dissolved in Borax Buffer", <u>Journal of Chromatography</u> , Vol. 586, Part 2, pp. 271-276 (1991).
		BALABAN, D., et al., "Nasogastric Omeprazole: Effects on Gastric pH in Critically Ill Patients", <u>The American Journal of Gastroenterology</u> , Vol. 92, No. 1, pp. 79-83 (1997).
		BALLARD, E., et al., "Bioequivalence Between Lansoprazole Sachet for Suspension and Intact Capsule", <u>Gastroenterology</u> , Vol. 120 (No. 5, Suppl. 1), pg. A-245 (2001).
		BALLESTEROS, et al., "Bolus or Intravenous Infusion of Rantidine: Effects on Gastric pH and Acid Secretion. A Comparison of Relative Efficacy and Cost", <u>Annals of Internal Medicine</u> , Vol. 112, No. 5, pp. 334 - 339 (1990).
		BARIE & HARIRI, "Therapeutic Use of Omeprazole For Refractory Stress-Induced Gastric Mucosal Hemorrhage", <u>Critical Care Medicine</u> , Vol. 20, No. 6, pp. 899-901 (1992).
		BEEKMAN, S. M., "Preparation and Properties of New Gastric Antacids I", <u>J. Pharm Assoc.</u> , Vol. 49, pp. 191-200, (1960).

	OT- Fan	Date Considered	9/29/03
--	---------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	2	of	12
-------	---	----	----

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936354

RECEIVED

JUL 29 2003

TECH CENTER 1600/290

NON PATENT LITERATURE


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
--------------------	-----------------------	--

↑		BLUM, A., "Therapeutic Approach to Ulcer Healing," <u>The American Journal of Medicine</u> , Volume 79 (Suppl. 2C), pp.8-14 (August 30, 1985)
		BONE, "Let's Agree on Terminology: Definition of Sepsis", <u>Critical Care Medicine</u> , Vol. 19, No. 7, pp. 973-976 (July 1991).
		BORRERO, et al., "Antacids vs. Sucralfate in Preventing Acute Gastrointestinal Tract Bleeding in Abdominal Aortic Surgery. A Randomized Trial in 50 Patients", <u>Arch. Surg.</u> , Vol. 121, pp. 810-12 (July 1986).
		BRUNTON, <u>The Pharmacologic Basis of Therapeutics</u> , p. 907 (1990).
		CANTU & KOREK, "Central Nervous System Reactions to Histamine-2 Receptor Blockers", <u>Annals of Internal Medicine</u> , Vol. 114, No. 12, pp. 1027-34 (1991).
		CAOS, A., et al., "Rabeprazole for the Prevention of Pathologic and Symptomatic Relapse of Erosive or Ulcerative Gastroesophageal Reflux Disease", <u>The American Journal of Gastroenterology</u> , Vol. 95, No. 11, pp. 3081-3088 (2000).
		CARROLL, M., et al., "Nasogastric Administration of Omeprazole for Control of Gastric pH" 10 th <u>World Congresses of Gastroenterology</u> , Abstracts (October 2-7, 1994).
		CEDERBERG, C., et al., "Omeprazole: Pharmacokinetics and Metabolism in Man", <u>Scand. J. Gastroenterol.</u> , Vol. 24, Suppl. 166, pp. 33-40 (1989).
		CEDERBERG, et al., "Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intra-gastric Acidity in Healthy Subjects", <u>Scand. J. Gastroenterol.</u> , Vol. 28, No. 2, pp. 179-184 (February 1993).
		CHING, et al., "Antacids - Indications and Limitations", <u>Drugs</u> , Vol. 47, No. 2, pp. 305-317 (February 1994).
		CIOFFI, et al., "Comparison of Acid Neutralizing and Non-acid Neutralizing Stress Ulcer Prophylaxis in Thermally Injured Patients", <u>The Journal of Trauma</u> , Vol. 36, pp. 541-47 (1994).
		COOK, et al., "Nosocomial Pneumonia and the Role of Gastric pH: A Meta Analysis", <u>Chest</u> , Vol. 100, No. 1, pp. 7-13 (July 1991).
		COOK, et al., "Risk Factors For Gastrointestinal Bleeding in Critically Ill Patients. Canadian Critical Care Trial Groups", <u>The New England Journal of Medicine</u> , Vol. 330, No. 6, pp. 377-81 (February 10, 1994).
		COOK, et al., "Stress Ulcer Prophylaxis in the Critically Ill: A Meta Analysis", <u>The American Journal of Medicine</u> , Vol. 91, pp. 519-527 (November 1991).
		CRILL, et al., "Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients", <u>Pharmacotherapy</u> , Vol. 19, No. 2, pp. 162-180 (February 1999).
↓		CZAJA, et al., "Acute Gastroduodenal Disease After Thermal Injury: An Endoscopic Evaluation of Incidence and Natural History", <u>The New England Journal of Medicine</u> , Vol. 291, pp. 925-929 (October 31, 1974).

	<i>J. Fan</i>	Date Considered	9/29/03
--	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/054,350
			Filing Date	01/19/2002
			First Named Inventor	Jeffery O. Phillips
			Art Unit	1625
			Examiner Name	Fan, J.
			Attorney Docket Number	02936354
Sheet	3	of	12	

RECEIVED
JUL 29 2003
TECH CENTER 1600/2900

NON PATENT LITERATURE		
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

↑ D.G. reviewed. Cursory ↓		DEAKIN, et al., "Therapeutic Progress – Review XXXIII: Are We Making Progress In The Drug Treatment of Oesophageal Disease?", <u>Journal of Clinical Pharmacy and Therapeutics</u> , Vol. 13, No. 6, pp. 365-374 (December 1988).
		DI IORIO, et al., "Aluminum and Phosphorus Urinary Excretion After Modifying Gastric Acid Secretion In Chronic Renal Failure", <u>Trace Elements and Electrolytes</u> , Vol. 13, No. 2, pp. 96-101 (1996).
		DI IORIO, et al., "Aluminum and Phosphorus Urinary Excretion After Modifying Gastric Acid Secretion In Normal Subjects", <u>Trace Elements and Electrolytes</u> , Vol. 13, No. 1, pp. 47-49 (1996).
		DIGIACINTO, et al., "Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes", <u>Annals of Pharmacotherapy</u> , Vol. 34, No. 5, pp. 600-605 (May 2000).
		DOAN, et al., "Comparative Pharmacokinetics and Pharmacodynamics of Lansoprazole Oral Capsules and Suspension in Healthy Subjects", <u>American Journal of Health-System Pharmacists</u> , Vol. 58, No. 16, pp. 1512-19 (August 15, 2001).
		DOBKIN, et al., "Does pH Paper Accurately Reflect Gastric pH?", <u>Critical Care Medicine</u> , Vol. 18, pp. 985-88 (September 1990).
		DRIKS, et al., "Nosocomial Pneumonia in Intubated Patients Given Sucralfate As Compared With Antacids or Histamine Type 2 Blockers. The Role of Gastric Colonization", <u>New England Journal Medicine</u> , Vol. 317, pp. 1376-82 (1987).
		EISENBERG, et al., "Prospective Trial Comparing a Combination pH Probe-Nasogastric Tube With Aspirated Gastric pH in Intensive Care Unit Patients", <u>Critical Care Medicine</u> , Vol. 18, No. 10, 1092-95 (1990).
		EPKE, A., et al., "Effect of Various Salts on the Stability of Lansoprazole, Omeprazole, and Pantoprazole as Determined by High-Performance Liquid Chromatography", <u>Drug Development and Industrial Pharmacy</u> , Vol. 25, No. 9, pp. 1057-1065 (1999).
		FABIAN, et al., "Pneumonia and Stress Ulceration in Severely Injured Patients. A Prospective Evaluation of the Effects of Stress Ulcer Prophylaxis", <u>Arch. Surg.</u> , Vol. 128, p. 185-91 (1993).
		FELLENIOUS, et al., "Substituted Benzimidazoles Inhibit Gastric Acid Secretions by Blocking H+/K+-ATPase", <u>Nature</u> , Vol. 290, Part 5802, pp. 159-61 (1981).
		FIDDIAN-GREEN, et al., "Predictive Value of Intramural pH and Other Risk Factors For Massive Bleeding From Stress Ulceration", <u>Gastroenterology</u> , Vol. 85, No. 3, pp. 613-20 (1983).
		FITTON, A., et al., "Pantoprazole, A Review of its Pharmacological Properties and Therapeutic Use in Acid-Related Disorders", <u>Drugs</u> , Vol. 51, No. 3, pp. 460-482 (March 1996).
		FRYKLUND, et al., "Function and Structure of Parietal Cells After H+/K+-ATPase Blockade", <u>American Journal of Physiology</u> , Vol. 254, pp. G399-407 (1988).
		FUCHS, C., "Antacids, Their Function, Formulation and Evaluation", <u>Drug and Cosmetic Industry</u> , Vol. 64, pp. 692-773, (1949).

		Date Considered	9/29/03
--	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

JUL 25 2003

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	4	of	12	Application Number	10/054,350
				Filing Date	01/19/2002
				First Named Inventor	Jeffery O. Phillips
				Art Unit	1625
				Examiner Name	Fan, J.
				Attorney Docket Number	02936354

NON PATENT LITERATUREExaminer
Initials*Cite
No.¹


Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

↑		GAFTER, et al., "Thrombocytopenia Associated with Hypersensitivity to Rantidine: Possible Cross-Reactivity With Cimetidine", <u>American Journal of Gastroenterology</u> , Vol. 84, No. 5, pp. 560-62 (1989).
		GARNER, et al., "CDC Definitions for Nosocomial Infections", <u>American Journal Infection Control</u> , Vol. 16, No. 7, pp. 128-40 (1988).
		GARNETT, "Efficacy, Safety, and Cost Issues in Managing Patients With Gastroesophageal Reflux Disease", <u>Am. J. Hosp. Pharm.</u> , Vol. 50, No. 4 (Suppl. 1), pp. S11-18 (April 1993).
		GRAY, et al., "Influence of Insulin Antibodies on Pharmacokinetics and Bioavailability of Recombinant Human and Highly Purified Beef Insulins in Insulin Dependent Diabetics", <u>British Medical Journal</u> , Vol. 290, pp. 1687-91 (June 8, 1985).
		GRAY, et al., "Influence of Insulin Antibodies on Pharmacokinetics and Bioavailability of Recombinant Human...", <u>British Medical Journal</u> , 290: 1687-1690 (1985).
		HARDY, et al., "Inhibition of Gastric Secretion by Omeprazole and Efficiency of Calcium Carbonate on the Control of Hyperphosphatemia in Patients on Chronic Hemodialysis", <u>Artificial Organs</u> , Vol. 22, No. 7, pp. 569-573 (July 1998).
		HATLEBAKK, J., et al., "Lansoprazole Capsules and Amoxicillin Oral Suspension in the Treatment of Peptic Ulcer Disease", <u>Scand. J. Gastroenterol.</u> , Vol. 30, No. 11, pp. 1053-57 (1995).
		HEATH, et al., "Intragastric pH Measurement Using a Novel Disposable Sensor", <u>Intensive Care Medicine</u> , Vol. 14, No. 3, pp. 232-35 (1988).
		HIXSON, et al., "Current Trends in the Pharmacotherapy for Gastroesophageal Reflux Disease", <u>Arch. Intern. Med.</u> , Vol. 152, No. 4, pp. 717-723 (April 1992).
		HIXSON, et al., "Current Trends in the Pharmacotherapy for Peptic Ulcer Disease", <u>Arch. Intern. Med.</u> , Vol. 152, No. 4, pp. 726-732 (April 1992).
		HOLBERT, J., et al., "A Study of Antacid Buffers: I. The Time Factor in Neutralization of Gastric Acidity", <u>Journal of The American Pharmaceutical Association (Scientific Edition)</u> , Vol. 36, pp. 149-151 (1947).
		HOLT, S., et al., "Omeprazole, Overview and Opinion", <u>Digestive Diseases and Sciences</u> , Vol. 36, No. 4, pp. 385-393 (April 1991).
		HORN, J., "The Proton-Pump Inhibitors: Similarities and Differences", <u>Clinical Therapeutics</u> , Vol. 22, No. 3, pp. 266-280 (2000).
		HOWDEN, et al., "Oral Pharmacokinetics of Omeprazole", <u>European Journal of Clinical Pharmacology</u> , Vol. 26, pp. 641-643 (1984).
		HUMPHRIES, et al., "Review Article: Drug Interactions With Agents Used to Treat Acid-Related Diseases", <u>Alimentary Pharmacology & Therapeutics</u> , Vol. 13, Suppl. 3, pp. 18-26 (August 1999).
		JUNGnickel, P., "Pantoprazole: A New Proton Pump Inhibitor", <u>Clinical Therapeutics</u> , Vol. 22, No. 11, pp. 1268-1293 (2000).

	<i>J. Fan</i>	Date Considered	9/29/03
--	---------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936354

RECEIVED

JUL 29 2003

TECH CENTER 1600/290

Sheet 5 of 12

NON PATENT LITERATURE

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
-----------------------	--------------------------	--

↑		KAROL, M. et al., "Pharmacokinetics of Lansoprazole in Hemodialysis Patients", <u>J Clin Pharmacol</u> , Vol. 35, pp. 815-820 (August 1995).
		KIHIRA, K., et al., "Endoscopic Topical Therapy for the Treatment of Helicobacter Pylori Infection", <u>Journal of Gastroenterology</u> , Vol. 31, Suppl 9, pp. 66-68 (November 1996).
		KILRICH, et al., "Effect of Intravenous Infusion of Omeprazole and Rantidine on Twenty-Four-Hour Intra gastric pH", <u>Digestion</u> , Vol. 56, pp. 25-30 (1995).
↓		KORPONAY-SZABO, I., et al., "High Acid Buffering Capacity of Protein Hydrolysate Infant Formulas", <u>Journal of Pediatric Gastroenterology and Nutrition</u> , Vol. 31, Supplement 2, Abstract 956 (August 5-9, 2000).
revised		KROMER, "Similarities and Differences in the Properties of Substituted Benzimidazoles: A Comparison Between Pantoprazole and Related Compounds", <u>Digestion</u> , Vol. 56, No. 6, pp. 443-454 (1995).
		KROMER, et al., "Differences in pH-Dependent Activation Rate of Substituted Benzimidazoles and Biological in vitro Correlates", <u>Pharmacology</u> , Vol. 56, pp. 57-70, (1998)
Cursor		LAGGNER, et al., "Prevention of Upper Gastrointestinal Bleeding in Long Term Ventilated Patients", <u>American Journal of Medicine</u> , Vol. 86, Suppl. 6A, pp. 81-84 (June 9, 1989).
		LANDAHL, S., et al., "Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers", <u>Clin. Pharmacokinet.</u> , Vol. 23, No. 6, pp. 469-476 (1992).
		LARSON, C., et al., "Bioavailability and Efficacy of Omeprazole Given Orally and By Nasogastric Tube", <u>Digestive Diseases and Sciences</u> , Vol. 41, No. 3, pp. 475-479 (March 1996).
		LARSON, et al., "Gastric Response to Severe Head Injury", <u>American Journal of Surgery</u> , Vol. 147, pp. 97-105 (January 1984).
		LARSSON, et al., "Gastric Acid Antisecretory Effect of Two Different Dosage Forms of Omeprazole During Prolonged Oral Treatment in the Gastric Fistula Dog", Vol. 23, No. 8, pp. 1013-1019 (1988).
		LASKY, M., et al., "A Prospective Study of Omeprazole Suspension to Prevent Clinically Significant Gastrointestinal Bleeding From Stress Ulcers in Mechanically Ventilated Trauma Patients", <u>The Journal of Trauma: Injury Infection, and Critical Care</u> , Vol. 44, No. 3, pp. 527-533 (March 1998).
		LIN, M., et al., "Evaluation of Buffering Capacity and Acid Neutralizing pH Time Profile of Antacids", <u>J Formos Med Assoc</u> , Vol. 97, No. 10, pp. 704-710 (1998).
		LIND, et al., "Inhibition of Basal and Betazole - and Sham-Feeding-Induced Acid Secretion by Omeprazole in Man", <u>Scand. J. Gastroenterol</u> , Vol. 21, No. 8, pp. 1004-1010 (1986).
		LOCKHART, S. et al., "A Lansoprazole Suspension Formulation As An Alternative to Capsules for Oral Administration", <u>World Congresses of Gastroenterology</u> , Abstract Exh A2074 (September 6-11, 1998).
✓		LONDONG, et al., "Dose-Response Study of Omeprazole on Meal-Stimulated Gastric-Acid Secretion and Gastrin Release", <u>Gastroenterology</u> , Vol. 85, No. 6, pp. 1373-1378 (1983).

		Date Considered	9/29/03
--	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936354

RECEIVED

JUL 29 2003

TECH CENTER 1600/290

Sheet 6 of 12

NON PATENT LITERATUREExaminer
Initials*Cite
No. ¹

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

↑		MACONI, et al., "Prolonging Proton Pump Inhibitor-Based Anti-Helicobacter Pylori Treatment From One to Two Weeks in Duodenal Ulcer: Is It Worthwhile?", <u>Digest Liver Disease</u> , Vol. 32, pp. 275-280 (May 2000).
		MARRONE & SILEN, "Pathogenesis, Diagnosis and Treatment of Acute Gastric Mucosa Lesions", <u>Clinics Gastroenterology</u> , Vol. 13, No. 2, pp. 635-50 (May 1984).
		MARTIN, A., et al., <u>Physical Pharmacy - Physical Chemicals Principles in the Pharmaceutical Sciences</u> , Fourth Edition, (1993)
os		MARTIN, L., et al., "Continuous Intravenous Cimetidine Decreases Stress-Related Upper Gastrointestinal Hemorrhage Without Promoting Pneumonia", <u>Critical Care Medicine</u> , Vol. 21, Vol. 1, pp. 19-30 (1993).
reviewed		MAXWELL, et al., "Control of Gastric pH In A Critical Care Unit: Physician Behavior and Pharmacologic Effectiveness", <u>Am. Rev. Respir. Dis.</u> , Vol. 143, No. 4 (Part 2), pg. A482 (1991).
		MCANDREWS, et al., "Omeprazole and Lansoprazole Suspensions for Nasogastric Administration", <u>American Journal of Health-System Pharm.</u> , Vol. 56, pg. 81 (January 1, 1999).
		MCTAVISH, D., et al., "Omeprazole, An Updated Review of its Pharmacology and Therapeutic Use in Acid-Related Disorders" by Drugs, Vol. 42, No. 1, pp. 138-170 (1991).
		MEINERS, et al., "Evaluation of Various Techniques to Monitor Intragastric pH", <u>Arch. Surg.</u> , Vol. 117, No. 3, pp. 288-91 (1982).
Carsing		METZLER, M., Advances in the use of PPI's From Efficacy to Effectiveness, <u>Presentation: Simplified Omeprazole Suspension</u> (1999).
		MOHIUDDIN, M. A., et al., "Effective Gastric Acid Suppression After Oral Administration of Enteric-Coated Omeprazole Granules", <u>Digestive Diseases and Sciences</u> , Vol. 42, No. 4, pp. 715-719 (April 1997).
		NAKAGAWA, et al., "Lansoprazole - Phase I Study of Lansoprazole (AG-1749) - Antiulcer Agent", <u>Journal of Clinical Therapeutics & Medicines</u> , Vol. 7, No. 1, pp. 33-50 (1991).
		NAKAMURA, M, et al., "Effect of Combined Administration of Lansoprazole and Sofalcone on Microvascular and Connective Tissue Regeneration After Ethanol-induced Mucosal Damage", <u>Journal of Clinical Gastroenterology</u> , Vol. 27, Suppl. 1, pp. 170-77 (1998).
		NAUNTON, M., et al., "Overuse of Proton Pump Inhibitors", <u>Journal of Clinical Pharmacy and Therapeutics</u> , Vol. 25, pp. 333-340 (2000).
		OH & CARROLL, "Electrolyte and Acid-base Disorders", <u>The Pharmacologic Approach to the Critically Ill Patient</u> , pp. 957-68 (Chernow, B. ed. 1994).
		OOSTERHUIS, et al. "Omeprazole: Pharmacology, Pharmacokinetics and Interactions", <u>Digestion</u> , Vol. 44, Suppl. 1, pp. 9-17 (1989).
✓		OSLER, et al., "Effect of Omeprazole On The Phosphate-Binding Capacity of Calcium Carbonate", <u>Nephron</u> , Vol. 69, pp. 89-90 (1995).

Examiner Initials	J. T. Fan	Date Considered	9/29/03
-------------------	-----------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO

JUL 25 2003

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	7	of	12	Application Number	10/054,350
				Filing Date	01/19/2002
				First Named Inventor	Jeffery O. Phillips
				Art Unit	1625
				Examiner Name	Fan, J.
				Attorney Docket Number	02936354

NON PATENT LITERATUREExaminer
Initials*Cite
No.¹


Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

↑		OSTRO, et al., "Control of Gastric pH With Cimetidine: Boluses Versus Primed Infusions", <u>Gastroenterology</u> , Vol. 89, No. 3, pp. 532-37 (1985).
		PAUL, J., et al., "Pantoprazole Bicarbonate Suspension (PBS) Provides Oral Bioavailability Comparable To Tablet", <u>Critical Care Medicine</u> , (Feb. 2001).
		PECKMAN, H., "Alternative method for administering proton-pump inhibitors through nasogastric tubes" <u>Am J Health-Syst Pharm</u> Vol. 56, pp. 1020, (May 15 1999).
↓		PEURA & JOHNSON, "Cimetidine for Prevention and Treatment of Gastroduodenal Mucosal Lesions in Patients In an Intensive Care Unit", <u>Ann. Intern. Med.</u> , Vol. 103, pp. 173-177 (1985).
		PHILLIPS, D. H., "Interaction of Omeprazole with DNA in Rat Tissues", <u>Mutagenesis</u> , Vol. 7, No. 4, pp. 277-283 (July 1992).
reviewed		PHILLIPS, J., & METZLER, M., Poster Presentation presented at the Society for Critical Care Medicine Annual Meeting relating to SOS, (Jan 1999).
		PHILLIPS, J., et al., "A Multicenter, Prospective, Randomized Clinical Trial of Continuous Infusion I.V. Ranitidine vs. Omeprazole Suspension in the Prophylaxis of Stress Ulcers", <u>Critical Care Medicine</u> , Vol. 26, No. 1 (Suppl.), p. A101, No. 222 (1998).
		PHILLIPS, J., et al., "A Prospective Study of Simplified Omeprazole Suspension for the Prophylaxis of Stress-related Mucosal Damage", <u>Critical Care Medicine</u> , Vol. 24, No. 11, pp. 1793-1800 (1996).
Cursey		PHILLIPS, J., et al., "Simplified Omeprazole Solution For The Prophylaxis of Stress-Related Mucosal Damage In Critically Ill Patients", <u>Critical Care Medicine</u> , Vol. 22, No. 1, p. A53 (January 1994).
		PHILLIPS, J., et al., "The Stability of Simplified Lansoprazole Suspension (SLS)", <u>Gastroenterology</u> , Vol. 116, No. 4, pg. G0382 (April 1999).
		PHILLIPS, J., et al., "The Stability of Simplified Omeprazole Suspension (SOS)", <u>Critical Care Medicine</u> , Vol. 26, No. 1 (Suppl.), pg. A101, No. 221 (1998).
		PHILLIPS, J., Presentation: " Problems with Administering Granules", <u>Overview of Omeprazole Suspension</u> , (1999/2000).
		PHILLIPS, J., Presentation: "From Efficacy to Effectiveness Alternative Dosing of PPI's, <u>Overview of Omeprazole Suspension</u> , (Aug 1998).
		PHILLIPS, J., Presentation: "Simplified Omeprazole Suspension (SOS)", (1998).
		PHILLIPS, J., Presentation: "Stress-related Mucosal Damage, Optimizing Drug Therapy, <u>Prophylaxis of Stress Ulcers</u> , (1997)
		PHILLIPS, J., Presentation: "Stress-related Mucosal Damage, Optimizing Drug therapy in the 1990's, <u>The University of Missouri Surgical Society Scientific Program</u> , (June 1994).
✓		PHILLIPS, J., Presentation: "Update on Acid-related Disorders, Optimizing Pharmacotherapy for the 1990's, <u>A Model for Optimizing Pharmacotherapy</u> , (1996)

	<i>J. Fan</i>	Date Considered	9/29/03
--	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/054,350
		Filing Date	01/19/2002
		First Named Inventor	Jeffery O. Phillips
		Art Unit	1625
		Examiner Name	Fan, J.
		Attorney Docket Number	02936354
Sheet	8	of	12

RECEIVED

JUL 29 2003

TECH CENTER 1600/

NON PATENT LITERATURE


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
--------------------	-----------------------	--

↑		PHILLIPS, Project #5122: "Simplified Omeprazole Solution (S.O.S.) - Pharmacokinetic/Pharmacodynamic Study in Patients at Risk for Stress Related Mucosal Damage (SRMD)" (Approved 4/28/94).
		PICKWORTH, et al., "Occurrence of Nosocomial Pneumonia in Mechanically Ventilated Trauma Patients: A Comparison of Sucralfate and Ranitidine", <u>Critical Care Medicine</u> , Vol. 21, No.12, , pp. 1856-62 (1993).
8-2		PILBRANT, "Principles for Development of Antacids", <u>Scand. J. Gastroenterol Suppl.</u> , Vol. 75, pp. 32-36 (1982).
8-2		PILBRANT, A., et al., "Development of An Oral Formulation of Omeprazole", <u>Scand. J. Gastroenterol</u> , Vol. 20, (Suppl. 108) pp. 113-120 (1985).
reviewed.		PIPKIN, et al., "Onset of Action of Antisecretory Drugs: Beneficial Effects of a Rapid Increase in Intragastric pH in Acid Reflux Disease", <u>Scand. J. Gastroenterol. Suppl.</u> , Vol. 230, pp. 3-8 (1999).
		Presentation on Overview of Omeprazole Suspension, "Pharmacotherapy Related Outcomes Group Researching Effective Stress ulcer Strategies, (2000).
		Presentation on Overview of Omeprazole Suspension, Stress Ulcer Prophylaxis in the 21 st Century", (2001).
Cursey		PRICHARD, et al., "Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosage", <u>Gastroenterology</u> , Vol. 88, Part 1, pp. 64-69 (1985).
		PRIEBE & SKILLMAN, "Methods of Prophylaxis in Stress Ulcer Disease", <u>World J. Surg.</u> , Vol. 5, Part 2, pp. 223-33 (March 1981).
		QUERCIA, R. A., et al., "Stability of Omeprazole in an Extemporaneously Prepared Oral Liquid", <u>American Journal of Health-System Pharmacy</u> , Vol. 54, pp. 1833-1836 (August 15, 1997).
		REGARDH, C., et al., "The Pharmacokinetics of Omeprazole in Humans - A Study of Single Intravenous and Oral Doses", <u>Therapeutic Drug Monitoring</u> , Vol. 12, No. 2, pp. 163-172 (1990).
		REGARDH, et al., "Pharmacokinetics and Metabolism of Omeprazole in Animals and Man - An Overview", <u>Scand. J. Gastroenterology</u> , Vol. 108, pp. 79-94 (1985).
		RODRIGO, et al., "Therapeutic Approach to Peptic Ulcer Relapse", <u>Methods Find Exp. Clinical Pharmacology</u> , Vol. 11 (Supp. 1), pp. 131-135 (1989).
		ROHAN, E., "Nasogastric Administration of Omeprazole", <u>The Australian Journal of Hospital Pharmacy</u> , Vol. 28, No. 3, pp. 174-176 (1998).
		ROY, P., et al., "Zollinger-Ellison Syndrome - Clinical Presentation in 261 Patients", <u>Medicine</u> , Vol. 79, No. 6, pp. 379-411 (2000).
		RYAN, et al., "Nosocomial Pneumonia During Stress Ulcer Prophylaxis With Cimetidine and Sucralfate", <u>Arch. Surg.</u> , Vol. 128, pp. 1353-57 (December 1993).
✓		SAX, "Clinically Important Adverse Effects and Drug Interactions With H2-receptor Antagonists: An Update", <u>Pharmacotherapy</u> , Vol. 7, No. 6, Part 2, pp. 110S-115S (1987).

	<i>OT-Fan</i>	Date Considered	9/29/03
--	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	9	of	12	Application Number	10/054,350
				Filing Date	01/19/2002
				First Named Inventor	Jeffery O. Phillips
				Art Unit	1625
				Examiner Name	Fan, J.
				Attorney Docket Number	02936354

NON PATENT LITERATURE

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
-----------------------	--------------------------	--

↑		SCHEPP, "Stress Ulcer Prophylaxis: Still a Valid Option in the 1990s?", <u>Digestion</u> , Vol. 54, No. 4, pp. 189-99 (1993).
		SCHMASSMANN, et al., "Antacid Provides Better Restoration of Glandular Structures Within the Gastric Ulcer Scar Than Omeprazole", <u>Gut</u> , Vol. 35, No. 7, pp. 896-904 (July 1994).
		SCHMASSMANN, et al., "Antacids in Experimental Gastric Ulcer Healing: Pharmacokinetics of Aluminum and Quality of Healing", <u>European Journal of Gastroenterology & Hepatology</u> , Vol. 5, Suppl. 3, pp. S111-S116 (1993).
86		SCHUSTER, "Stress Ulcer Prophylaxis: In Whom? With What?", <u>Critical Care Medicine</u> , Vol. 21, Part 1, pp. 4-6 (January 1993).
		SECHET, et al., "Inhibition of Gastric Secretion by Omeprazole and Efficacy of Calcium Carbonate in the Control of Hyperphosphatemia in Patients on Maintenance Hemodialysis", <u>Nephrologie</u> , Vol. 20, No. 4, pp. 213-216 (1999).
		SECHET, et al., Role of the Time of Administration of Calcium Carbonate in the Control of Hyperphosphatemia in Patients on Maintenance Hemodialysis", <u>Nephrologie</u> , Vol. 20, No. 4, pp. 209-212 (1999).
		SHARMA, et al., "Oral Pharmacokinetics of Omeprazole and Lansoprazole After Single and Repeated Doses as Intact Capsules or As Suspensions in Sodium Bicarbonate", <u>Alimentary Pharmacology & Therapeutics</u> , Vol. 14, No. 7, pp. 887-892 (July 2000).
		SHARMA, et al., "The Pharmacodynamics of Lansoprazole Administered Via Gastrostomy as Intact, Non-Encapsulated Granules", <u>Alimentary Pharmacology Therapy</u> , Vol. 12, pp. 1171-1174 (1998).
		SHARMA, V., et al., "Effect on 24-hour Intragastric Acidity of Simplified Omeprazole Solution (SOS) Administered Via Gastrostomy", <u>AJG</u> , Vol. 92, No. 9, p. 1625, Section 169 (1997).
		SHARMA, V., et al., "Simplified Lansoprazole Suspension – A Liquid Formulation of Lansoprazole – Effectively Suppresses Intragastric Acidity When Administered Through a Gastrostomy", <u>The American Journal of Gastroenterology</u> , Vol. 94, No. 7, pp. 1813-1817 (July 1999).
		SHARMA, V., et al., "Simplified Lansoprazole Suspension (SLS): A Proton Pump Inhibitor (PPI) In A Liquid Formulation That Works", <u>AJG</u> , p. 1647, Section 153 (September 1998).
		SHARMA, V., et al., "The Effects on Intragastric Acidity of Per-Gastrostomy Administration of An Alkaline Suspension of Omeprazole", <u>Aliment Pharmacol Ther</u> , Vol. 13, pp. 1091-1095 (1999).
		SHARMA, V., "Comparison of 24-hour Intragastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole", <u>American Journal of Health-System Pharmacists</u> , Vol. 56, Suppl 4, pp. S18-S21 (December 1, 1999).
		SHUMAN, et al., "Prophylactic Therapy for Acute Ulcer Bleeding: A Reappraisal", <u>Annals of Internal Medicine</u> , Vol. 106, Vol. 4, pp. 562-67 (1987).
✓		SIEPLER, "A Dosage Alternative for H-2 Receptor Antagonists, Continuous-Infusion", <u>Clinical Therapy</u> , Vol. 8, Suppl. A, pp. 24-33 (1986).

	<i>J. Fan</i>	Date Considered	7/29/03
--	---------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUL 25 2003

PTO/SB/08B
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet	10	of	12	Application Number	10/054,350
				Filing Date	01/19/2002
				First Named Inventor	Jeffery O. Phillips
				Art Unit	1625
				Examiner Name	Fan, J.
				Attorney Docket Number	02936354

RECEI

JUL 29 2

TECH CENTER 16

NON PATENT LITERATURE

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
-----------------------	--------------------------	--

↑		SIEPLER, et al., "Selecting Drug Therapy for Patients With Duodenal Ulcers", <u>Clinical Pharmacy</u> , Vol. 9, No. 6, pp. 463-467 (June 1990).
		SIH, J., et al., "Studies on (H(+)-K+)-ATPase Inhibitors of Gastric Acid Secretion. Prodrugs of 2-[(2-Pyridinylmethyl)sulfinyl]benzimidazole Proton-Pump Inhibitors", <u>Journal of Medicinal Chemistry</u> , Vol. 34, No. 3, pp. 1049-1062 (March 1991).
		SIMMS, et al., "Role of Gastric Colonization in the Development of Pneumonia in Critically Ill Trauma Patients: Results of a Prospective Randomized Trial", <u>The Journal of Trauma</u> , Vol. 31, No. 4, pp. 531-36 (1991).
		SKILLMAN, et al., "Respiratory Failure, Hypotension, Sepsis and Jaundice: A Clinical Syndrome Associated With Lethal...", <u>Am. J. Surg.</u> , Vol. 117, Vol. 4, pp. 523-30 (1969).
		SKILLMAN, et al., "The Gastric Mucosal Barrier: Clinical and Experimental Studies In Critically Ill and Normal Man...", <u>Ann. Surg.</u> , Vol. 172, Vol. 4, pp. 564-84 (1970).
		SMYTHE & ZAROWITZ, "Changing Perspectives of Stress Gastritis Prophylaxis", <u>The Annals of Pharmacotherapy</u> , Vol. 28, pp. 1073-84 (September 1994).
		SPENCER, C., et al., "Esomeprazole", <u>Drugs 2000</u> , Vol. 60, No. 2, pp. 321-329 (August 2000).
		SPYCHAL & WICKMAN, "Thrombocytopenia Associated With Rantidine", <u>British Medical Journal</u> , Vol. 291, p. 1687 (December 14, 1985).
		STRATFORD, M. R., et al., "Nicotinamide Pharmacokinetics in Humans: Effect of Gastric Acid Inhibition, Comparison of Rectal vs Oral Administration and the Use of Saliva for Drug Monitoring", <u>Br. J. Cancer</u> , Vol. 74, No. 1, pp. 16-21 (July 1996).
		TAKEUCHI, et al., "Effects of Pantoprazole, A Novel H+/K+-ATPase Inhibitor, On Duodenal Ulcerogenic and Healing Responses in Rats: A Comparative Study with Omeprazole and Lansoprazole", <u>Journal of Gastroenterology and Hepatology</u> , Vol. 14, No. 3, p. 251-57 (1999).
		TANAKA, et al., "Pathogenesis of The Earliest Epithelial Cell Damage Induced by Mepirizole and Cysteamine in the Rat Duodenum", <u>Japanese Journal of Pharmacology</u> , Vol. 51, No. 4, pp. 509-519 (December 1989).
		TANAKA, M., et al., "Differential Stereoselective Pharmacokinetics of Pantoprazole, a Proton Pump Inhibitor in Extensive and Poor Metabolizers of Pantoprazole - A Preliminary Study", <u>Chirality</u> , Vol. 9, pp. 17-21 (1997).
		THOMSON, "Are The Orally Administered Proton Pump Inhibitors Equivalent? A Comparison of Lansoprazole, Omeprazole, Pantoprazole, and Rabeprazole", <u>Current Gastroenterology Reports</u> , Vol. 2, No. 6, pp. 482-493 (December 2000).
		TRYBA, "Risk of Acute Stress Bleeding and Nosocomial Pneumonia in Ventilated Intensive Care Patients. Sucralfate vs. Antacids", <u>American Journal of Medicine</u> , Vol. 87 (3B) 117-24 (1987).
↓		TRYBA, "Stress Ulcer Prophylaxis - Quo Vadis?", <u>Intensive Care Medicine</u> , Vol. 20, pp. 311-13 (1994).

	<i>OT-Fan</i>	Date Considered	9/29/03
--	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JUL 25 2003

Substitute for form 1449/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/054,350
			Filing Date	01/19/2002
			First Named Inventor	Jeffery O. Phillips
			Art Unit	1625
			Examiner Name	Fan, J.
			Attorney Docket Number	02936354
Sheet	11	of	12	

NON PATENT LITERATURE		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

↑		TYTGAT, G., "Drug Therapy of Reflux Oesophagitis: An Update," <u>Scand J. Gastroenterol.</u> , Vol. 24 (Suppl.168), pp. 38-49 (1989).
		VIAL, et al., "Side Effects of Ranitidine", <u>Drug Safety</u> , Vol. 6, pp. 94-117 (March/April 1991).
		VINCENT, et al., "Concurrent Administration of Omeprazole and Antacid Does Not Alter The Pharmacokinetics and Pharmacodynamics Of Dofetilide in Healthy Subjects", <u>Clinical Pharmacology & Therapeutics</u> , Vol. 59, No. 2 (Pii-93), pg. 182 (February 1996).
		WADE, Organic Chemistry, Pritice-Hall, Inc., Chapter 8, p. 349 (1987).
88		WALAN, "Pharmacological Agents For Peptic Ulcer Disease", <u>Scand. J. Gastroenterol. Suppl.</u> , Vol. 19, No. 98, pg. 1 (1984).
88		WALLMARK, et al., "The Relationship Between Gastric Acid Secretion and Gastric H+/K+-ATPase Activity", <u>Journal of Biological Chemistry</u> , Vol. 260, No. 25, pp. 13681-84 (1985).
reviewed		WATANABE, K., et al., "Pharmacokinetic Evaluation of Omeprazole Suspension Following Oral Administration in Rats: Effect of Neutralization of Gastric Acid", <u>Acta Med Okayama</u> , Vol. 50, No. 4, pp. 219-222 (August 1996).
		WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 [Date stamped in Howard University Library on January 13, 1995].
Cursory		WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in Walter Reed Army Medical Center Medical Library on January 17, 1995].
		WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in FDA Medical Library January 6, 1995].
		WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in University of Illinois on January 10, 1995].
		WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in Central DuPage Hospital Medical Library on January 10, 1995].
✓		WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in University of Missouri Health Sciences Library January 6, 1995].

OT-Fan	Date Considered	9/29/03
--------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

RECEIVED

JUL 29 2003

TECH CENTER

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 12 of 12

Complete if Known

Application Number	10/054,350
Filing Date	01/19/2002
First Named Inventor	Jeffery O. Phillips
Art Unit	1625
Examiner Name	Fan, J.
Attorney Docket Number	02936354

NON PATENT LITERATURE

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
Cursony reviewed	↑	WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Although allegedly date stamped in St. Vincent's Hospital Medical Library on January 3, 1995, interviews of library personnel revealed that this Supplement was not received until Jan. 9, 1995, as the January 9, 1995 date is found in their computerized database.]
		WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", Vol. 23, No. 1 (Suppl), p. A69 (January 1995).
		WILDER-SMITH & MERKI, "Tolerance During Dosing with H2 Receptor Antagonists: An Overview", <u>Scand. J. Gastroenterol.</u> , Vol. 193, pp. 14-19 (1992).
		YAMAKAWA, T., "Synthesis and Structure-Activity Relationships of Substituted 2-[2-imidazolylsulfanyl)methyl] Anilines As A New Class of Gastric H ⁺ /K ⁺ -ATPase Inhibitors. II.", <u>Chem Pharm Bull</u> (Tokyo), Vol. 40, No. 3, pp. 675-682 (March 1992).
		YASUDA, et al., "Antacids Have No Influence on the Pharmacokinetics of Rabeprazole, A New Proton Pump Inhibitor, In Healthy Volunteers", <u>International Journal of Clinical Pharmacology and Therapeutics</u> , Vol. 37, No. 5, pp. 249-253 (1999).
	✓	ZINNER, et al., "The Prevention of Upper Gastro-Intestinal Tract Bleeding in Patients in an Intensive Care Unit", <u>Surgery, Gynecology and Obstetrics</u> , Vol. 153, pp. 214-20 (August 1981).

RECEIVED

JUL 29 2003

TECH CENTER 1600/2900

	<i>J. Fan</i>	Date Considered	9/29/03
--	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.